Oxford, UK based Enara Bio announced a $32.5M series B to further its work developing TCR based therapies that target antigens found in the 'dark genome'
President & CEO Kevin Pojasek describes how the company searches for these novel cancer-specific antigens that are from areas of the genome that were previously thought to be non coding. Plus, new investors who have participated in the round and how it will enable to company to pursue its internal programs.